Company: PRTA
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001559053-25-000023
Chunk: 10

Company: PROTHENA CORP PUBLIC LTD CO
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 1
Chunk 10
---
(1)Purchase obligations consist of non-cancelable purchase commitments to suppliers and contract research organizations.

7. Significant Agreements

Roche License Agreement

In December 2013, the Company through its wholly owned subsidiary Prothena Biosciences Limited and Prothena Biosciences Inc entered into a License, Development, and Commercialization Agreement (the “ License Agreement”) with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. (together, “ Roche”) to develop and commercialize certain antibodies that target α- synuclein, including prasinezumab, which are referred to collectively as “ Licensed Products.” Upon the effectiveness of the License Agreement in January 2014, the Company granted to Roche an exclusive, worldwide license to develop, make, have made, use, sell, offer to sell, import and export the Licensed Products. The Company retained certain rights to conduct development of the Licensed Products and a n option to co-promote prasinezumab in the U. S. During the term of the License Agreement, the Company and Roche will work exclusively with each other to research and develop antibody products targeting alpha-synuclein (or α- synuclein) potentially including incorporation of Roche’s proprietary Brain Shuttle™ technology to potentially increase delivery of therapeutic antibodies to the brain. The License Agreement provided for Roche making an upfront payment to the Company of $ 30.0 15.0 30.0 60.0

For prasinezumab, Roche is obligated to pay:

• up to $ 290.0

• up to $ 155.0

• up to $ 175.0

• tiered, high single-digit to high double-digit royalties in the teens based on U. S. and ex-U. S. annual net sales, subject to certain adjustments, with respect to the applicable Licensed Product.

Roche bore 100 In May 2021, the Company exercised its rights under the terms of License Agreement to receive potential U. S. commercial sales milestone and royalties, in lieu of a U. S. profit and loss share for prasinezumab in Parkinson’s disease. Thus, in the U. S., through May 28, 2021, the parties shared all development costs, all of which were allocated 70 30

development and commercialization costs, as well as profits, all of which will be allocated 70 30

The Company initiated a Phase 1